Evidence map›Paper›PMID 26772532›Full record

ArticleJournal of molecular and cellular cardiology2016

IL-10 for cardiac autophagy modulation: New direction in the pursuit of perfection.

Anweshan Samanta, Buddhadeb Dawn

Open access · greenAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular and cellular cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anweshan SamantaDivision of Cardiovascular Diseases, Cardiovascular Research Institute, University of Kansas Medical Center and Hospital, Kansas City, KS, United States; Midwest Stem Cell Therapy Center, University of Kansas Medical Center and Hospital, Kansas City, KS, United States.
Buddhadeb DawnDivision of Cardiovascular Diseases, Cardiovascular Research Institute, University of Kansas Medical Center and Hospital, Kansas City, KS, United States; Midwest Stem Cell Therapy Center, University of Kansas Medical Center and Hospital, Kansas City, KS, United States. Electronic address: bdawn@kumc.edu.
The University of Kansas Health System · US

Funding

Infarct Repair with Mesenchymal Stem Cell SubpopulationR01HL117730 · NHLBI · UNIVERSITY OF NEVADA LAS VEGAS · PI DAWN, BUDDHADEB · 2013 to 2017
$1.9M
NHLBI NIH HHS R01 HL-117730NHLBI NIH HHS R01 HL117730
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiotensin IIAnimalsApoptosis Regulatory ProteinsAutophagyBeclin-1CardiomegalyGene Expression RegulationHeart FailureHumansInterleukin-10MiceMyocardiumMyocytes, CardiacProto-Oncogene Proteins c-bcl-2Receptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Angiotensin IIApoptosis Regulatory ProteinsBCL2 protein, humanBcl2 protein, mouseBeclin-1Becn1 protein, mouseIL10 protein, mouseInterleukin-10Proto-Oncogene Proteins c-bcl-2Receptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Angiotensin IIAutophagyCardiacIL-10Pressure overload

Identifiers

PMID26772532
PMCPMC4817493
OpenAlexW2237048010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.